KALARIS THERAPEUTICS, INC. Deferred Offering Costs
KALARIS THERAPEUTICS, INC. (KLRS) had Deferred Offering Costs of $0 as of 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Balance Sheet › Assets
us-gaap:DeferredOfferingCosts · last filed 2024-03-15
- 2023-12-31: Deferred Offering Costs $0.00.
- 2022-12-31: Deferred Offering Costs $0.00.
- 2021-12-31: Deferred Offering Costs $0.00.
- 2020-12-31: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-15 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-15 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-15 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-10 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-10 |
| 2020-06-30 | $1.30M 10-Q · filed 2020-09-02 |
| 2019-12-31 | $100.00K 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |